Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial.

Wake after sleep onset (WASO) declined significantly in response to the 400-mg dose relative to placebo (mean treatment effect –54 min; P < 0.001), and dose-related, clinically relevant, and nominally significant improvements were observed after almorexant doses of 200 ( P < 0.001) and 100 mg ( P = 0.004) ( Figure 1c ).

also in 7,732 other papers